COVID-19 Update: Kenney accepts Allard’s resignation, asks his chief of staff to step down

Article content continued

Moncef Slaoui, head of Operation Warp Speed, the federal vaccine program, said on CBS’ “Face the Nation” that officials were in talks with Moderna and the Food and Drug Administration about the idea. Moderna’s vaccine requires two injections.

“We know that for the Moderna vaccine, giving half of the dose to people between the ages of 18 and 55, two doses, half the dose, which means exactly achieving the objective of immunizing double the number of people with the doses we have,” Slaoui said.

“We know it induces identical immune response” to the full dose, he added.

Moderna and the FDA could not immediately be reached for comment.

Read more.


Tougher lockdown restriction likely on the way, says UK PM Johnson

Britain’s Prime Minister Boris Johnson. Photo by JEFF OVERS/BBC/AFP via Getty Images

LONDON — British Prime Minister Boris Johnson said on Sunday that tougher lockdown restrictions were probably on the way as COVID-19 cases keep rising, but that schools were safe and children should continue to attend.

Cases of COVID-19 in Britain are at record levels and increasing, fueled by a new and more transmissible variant of the virus. That has already forced the government to cancel the planned reopening of schools in and around London, with calls from teaching unions for wider closures.

Much of England is already under the toughest level of restriction set out in a four-tier system of regional regulations designed to stop the spread of the virus and protect the national healthcare system.

Read more.


India’s approval of homegrown vaccine criticized over lack of data

A health official prepares to administer a vaccine during a dry run or a mock drill for COVID-19 coronavirus vaccine delivery at a primary health centre in Kolkata on Jan. 2, 2021. Photo by DIBYANGSHU SARKAR/AFP via Getty Images

NEW DELHI — India on Sunday granted emergency approval to Bharat Biotech’s COVAXIN but faced questions from industry experts and opposition lawmakers after taking the step without publishing efficacy data for the homegrown coronavirus vaccine.

Read more.

View Source